RxDoctor Payments Data

Barry Blitz, MD

Urology · Fort Myers, FLNPI 1043302383

Payments from drug & device makers

$10,725in general payments, 2019–2025

Across 328 payments — averaging $32.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avyxa Pharma, LLC$3K
  • Valencia Technologies Corporation$1K
  • Endo Pharmaceuticals Inc.$638
  • Johnson & Johnson$548
  • Astellas Pharma US Inc$496
  • Endo USA, Inc.$407
  • plus $4K from 39 others

What the payments were for

  • Speaking & faculty fees$2,00019%
  • Travel & lodging$2,13320%
  • Food & beverage$6,55961%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,725 in reported general payments places this provider in the 70th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$664,370
Medicare patients
1,316
Services billed
10,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide106$1,400,987
ErleadaApalutamide31$467,236
OrgovyxRelugolix47$123,844
MyrbetriqMirabegron55$55,292
GemtesaVibegron20$21,371
Tamsulosin Hcl1,224$19,992
Silodosin183$11,458
Finasteride626$8,379
Fosfomycin Tromethamine23$6,163
Alfuzosin Hcl ErAlfuzosin Hcl193$5,328
Methenamine Hippurate57$5,273
Oxybutynin Chloride ErOxybutynin Chloride175$3,975
Testosterone23$3,690
Potassium Citrate ErPotassium Citrate24$3,522
Testosterone Cypionate46$2,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$496$1,456,279161 claims
Johnson & JohnsonErleada$548$467,23631 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$286$145,21567 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 urology providers in Florida.

Other urology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →